EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Upregulated NOTCH2 Expression Is Implicated in the Clinical Aggressiveness of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma

Yi-Pei Lee iD, Fahimeh Razegphpour, Emilia Sorescu, Markus Stücker, Thilo Gambichler

International Journal of Dermatology · 2025

DOI: 10.1111/ijd.17844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Yi-Pei Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venerology and Allergology, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Receptor, Notch2, Skin Neoplasms, Neoplasm Recurrence, Local, Sarcoma. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) represent clinicopathological variants of a spectrum. It is known that AFX and PDS tumors harbor frequent NOTCH1/2 mutations. However, the expression of Notch signaling pathway‐associated proteins in both tumor cells has not been studied before.

Methods

We conducted an immunohistochemical study by performing NOTCH1, NOTCH2, NICD, and HES1 staining on the most representative formalin‐fixed paraffin‐embedded (FFPE) tumor tissues out of sixty‐two patients with the first diagnosis of either AFX ( n = 33) or PDS ( n = 29) in a single tertiary medical center.

Results

Ten patients (PDS, n = 9; AFX, n = 1) had disease progression in terms of locoregional relapse, including local recurrence and regional lymph node metastasis, with a median time‐to‐(first)‐recurrence interval of 8 months after a wide local excision. Among all the Notch expression profiles, only the upregulated NOTCH2 expression has a positive correlation with disease progression [odds ratio (OR): 1.02, 95% confidence interval (CI): 1–1.04, p = 0.029]. Furthermore, HES1 is activated through the NOTCH2 signaling pathway ( r (60) = 0.27, p = 0.032) rather than NOTCH1, and NOTCH1 does not appear to be functionally active.

Conclusions

Upregulated NOTCH2 expression plays a significant role in disease progression, in part through the canonical signaling pathway involving the downstream effector HES1. Targeting NOTCH2 signaling might hold therapeutic promise in patients with disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Notch2Skin NeoplasmsNeoplasm Recurrence, LocalSarcomaHumansMaleFemaleMiddle AgedAgedUp-RegulationDisease ProgressionTranscription Factor HES-1AdultReceptor, Notch1Aged, 80 and overImmunohistochemistryLymphatic Metastasis

Stichwörter der Autor:innen

HES1NICDNOTCH1NOTCH2Notch‐targeted therapyatypical fibroxanthomapleomorphic dermal sarcoma

Substanzen

Receptor, Notch2NOTCH2 protein, humanTranscription Factor HES-1Receptor, Notch1NOTCH1 protein, humanHES1 protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Venerology and Allergology, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Department of Dermatology, Dortmund Hospital gGmbH, University Witten/Herdecke, Germany.

ORCID-Profile: Yi-Pei Lee

Zitieren

APA

Lee, Y. P., Razegphpour, F., Sorescu, E., Stücker, M., & Gambichler, T. (2025). Upregulated NOTCH2 Expression Is Implicated in the Clinical Aggressiveness of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma. International Journal of Dermatology. https://doi.org/10.1111/ijd.17844

Vancouver

Lee YP, Razegphpour F, Sorescu E, Stücker M, Gambichler T. Upregulated NOTCH2 Expression Is Implicated in the Clinical Aggressiveness of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma. International Journal of Dermatology. 2025. doi:10.1111/ijd.17844

BibTeX
@article{Lee2025,
  author = {Lee, Yi-Pei and Razegphpour, Fahimeh and Sorescu, Emilia and Stücker, Markus and Gambichler, Thilo},
  title = {Upregulated NOTCH2 Expression Is Implicated in the Clinical Aggressiveness of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma},
  journal = {International Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ijd.17844}
}
Kostenlos starten →